Enlivex Therapeutics Ltd
1BT
Company Profile
Business description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Contact
14 Einstein Street
Ness Ziona7403618
ISRT: +972 26208072
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,822.20 | 76.60 | 0.88% |
| CAC 40 | 7,953.77 | 14.16 | -0.18% |
| DAX 40 | 23,162.92 | 17.61 | -0.08% |
| Dow JONES (US) | 46,138.77 | 47.03 | 0.10% |
| FTSE 100 | 9,507.41 | 44.89 | -0.47% |
| HKSE | 25,878.50 | 47.85 | 0.19% |
| NASDAQ | 22,564.23 | 131.38 | 0.59% |
| Nikkei 225 | 50,071.57 | 1,533.87 | 3.16% |
| NZX 50 Index | 13,410.11 | 83.21 | 0.62% |
| S&P 500 | 6,642.16 | 24.84 | 0.38% |
| S&P/ASX 200 | 8,538.40 | 70.40 | 0.83% |
| SSE Composite Index | 3,956.18 | 9.44 | 0.24% |